瑞波西汀与氯丙咪嗪治疗抑郁症伴焦虑临床评价  

Clinical Evaluation on Reboxetine and Clomipramine in the Treatment of Depressive Disorder Associated with Anxiety

作　　者：左桂连[1] 林怀洁 

机构地区：[1]广东省汕头市第四人民医院,广东汕头515000 [2]广东省汕头市第二人民医院,广东汕头515000

出　　处：《河北医学》2008年第9期1036-1039,共4页Hebei Medicine

摘　　要：目的：比较瑞波西汀与氯丙咪嗪治疗抑郁症伴焦虑的疗效及其安全性。方法：将lll例抑郁症分为两组。瑞波西汀组56例，口服瑞波西汀8～12mg，2次／日；氯丙咪嗪组55例，口服氯丙咪嗪100～200mg，2次／日；均6周为1个疗程。结果：对抑郁症状的治疗，瑞波西汀组显效率73．2％，氯丙咪嗪组显效率67．3％，疗效差异无显著意义（P〉0．05）；对焦虑症状的治疗，瑞波西汀组显效率78．8％。氯丙咪嗪组显效率43．6％，疗效差异有显著性（P〈0．05），整体药物不良反应发生率两组相当。结论：瑞波西汀与氯丙咪嗪是安全有效的治疗抑郁症的药物，但抗焦虑作用瑞波西汀优于氯丙咪嗪。Objective ： To compare the clinical effects and adverse reactions of reboxetine and clomipramine in the treatment of depression associated with anxiety. Methods： One hundred and eleven Patients depression associated with anxiety were divided into 2 groups ： Fifty-six Patients were treated with reboxetine, 8 - 12mg, po, bid for 6 weeks ; fifty-five patients were treated with clomipramine, 100 - 200mg, po, bid for 6 weeks. Results：The marked effective rate of reboxetine group and clomipramine group were 73.2% and 67. 3% （p〉0.05） in treating depression symptoms, but the marked effective rate of reboxetine group and clomipramine group were 78.8% and 43.6% （p〈0.05） in treating anxiety symptoms. The adverse reactions in reboxetine group and clomipramine group should on significant difference. Couclusion： Reboxefine and clomipramine is a safe and effective drug for treatment of depression, but reboxetine is superior to clomipramine in reducing anxiety symptoms.

关 键 词：瑞波西汀 氯丙咪嗪 抑郁症 焦虑 

分 类 号：R749.4[医药卫生—神经病学与精神病学]